Experimental immune cell therapy aims to make risky cancer transplants safer
NCT ID NCT03533816
Summary
This early-stage study tests whether specially prepared immune cells called gamma delta T-cells can help patients with leukemia and related blood cancers after a partially matched bone marrow transplant. The goal is to boost the cancer-fighting effect of the transplant while reducing a dangerous complication called graft-versus-host disease. Researchers will enroll up to 38 adults aged 19-65 to determine the safety and best dose of these modified cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Medical Center
RECRUITINGColumbus, Ohio, 43210-1238, United States
-
University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.